Literature DB >> 18288784

A comprehensive genetic profile of phyllodes tumours of the breast detects important mutations, intra-tumoral genetic heterogeneity and new genetic changes on recurrence.

A M Jones1, R Mitter, R Springall, T Graham, E Winter, C Gillett, A M Hanby, I P M Tomlinson, E J Sawyer.   

Abstract

The aims of this study were to identify genetic changes associated with malignant progression of the fibroepithelial neoplasms, phyllodes tumours of the breast (PTs), and to ascertain whether genetic progression occurs when PTs recur locally. A further aim was to assess whether the genetic data support the classification of these tumours into three subtypes, benign, borderline and malignant. 126 PTs (37 benign, 41 borderline, 48 malignant) were analysed by either array-CGH or the Illumina Goldengate assay. The large-scale genetic changes associated with malignant/borderline phenotypes were +1q, +5p, +7, +8, -6, -9p, -10p and -13. Cluster analysis of the array-CGH data supported the division of malignant and borderline PTs into two separate groups, one comprising almost all malignant lesions and the other, benign and borderline tumours. Interstitial deletions of 9p21 that involved the p16INK4a locus were present in many malignant/borderline PTs, and some of these appeared to cause homozygous loss. Loss of expression of p16INK4a was found frequently and this was associated with 9p deletion; we also identified one p16INK4a mutation and evidence of methylation of p16INK4a in malignant PTs. Our evidence shows that inactivation of this gene is important in the development of malignant PTs. In selected PTs, multiple areas of stroma were isolated and analysed separately by array-CGH. We found considerable intra-tumoral genetic heterogeneity. Analysis of paired primary and recurrent tumours showed that recurrent tumours often acquired new genetic changes; in particular, benign tumours tended to acquire changes characteristic of the malignant/borderline phenotype. We believe it likely that unfavourable sub-clones not easily identified by histology account for the unpredictable clinical behaviour of these tumours. Copyright (c) 2008 Pathological Society of Great Britain and Ireland

Entities:  

Mesh:

Substances:

Year:  2008        PMID: 18288784     DOI: 10.1002/path.2320

Source DB:  PubMed          Journal:  J Pathol        ISSN: 0022-3417            Impact factor:   7.996


  25 in total

1.  Morphologic and genetic heterogeneity in breast fibroepithelial lesions-a comprehensive mapping study.

Authors:  Benjamin Yongcheng Tan; Nur Diyana Md Nasir; Huan Ying Chang; Cedric Chuan Young Ng; Peiyong Guan; Sanjanaa Nagarajan; Vikneswari Rajasegaran; Jing Yi Lee; Jing Quan Lim; Aye Aye Thike; Bin Tean Teh; Puay Hoon Tan
Journal:  Mod Pathol       Date:  2020-04-22       Impact factor: 7.842

2.  Ataxia telangiectasia mutated (ATM) inhibition transforms human mammary gland epithelial cells.

Authors:  Stefano J Mandriota; Raphaële Buser; Laurence Lesne; Christelle Stouder; Vincent Favaudon; Pierre Maechler; Frédérique Béna; Virginie Clément; Curzio Rüegg; Roberto Montesano; André-Pascal Sappino
Journal:  J Biol Chem       Date:  2010-02-22       Impact factor: 5.157

3.  Integrated analysis of copy number alteration and RNA expression profiles of cancer using a high-resolution whole-genome oligonucleotide array.

Authors:  Seung-Hyun Jung; Seung-Hun Shin; Seon-Hee Yim; Hye-Sun Choi; Sug-Hyung Lee; Yeun-Jun Chung
Journal:  Exp Mol Med       Date:  2009-07-31       Impact factor: 8.718

4.  Phyllodes tumor of the breast.

Authors:  Grzegorz Korpanty; Derek G Power; Conleth Murphy; Malcolm Kell; John McCaffrey
Journal:  Med Oncol       Date:  2010-10-02       Impact factor: 3.064

5.  Genomic landscapes of breast fibroepithelial tumors.

Authors:  Jing Tan; Choon Kiat Ong; Weng Khong Lim; Cedric Chuan Young Ng; Aye Aye Thike; Ley Moy Ng; Vikneswari Rajasegaran; Swe Swe Myint; Sanjanaa Nagarajan; Saranya Thangaraju; Sucharita Dey; Nur Diyana Md Nasir; Giovani Claresta Wijaya; Jing Quan Lim; Dachuan Huang; Zhimei Li; Bernice Huimin Wong; Jason Yong Sheng Chan; John R McPherson; Ioana Cutcutache; Gregory Poore; Su Ting Tay; Wai Jin Tan; Thomas Choudary Putti; Buhari Shaik Ahmad; Philip Iau; Ching Wan Chan; Anthony P H Tang; Wei Sean Yong; Preetha Madhukumar; Gay Hui Ho; Veronique Kiak Mien Tan; Chow Yin Wong; Mikael Hartman; Kong Wee Ong; Benita K T Tan; Steven G Rozen; Patrick Tan; Puay Hoon Tan; Bin Tean Teh
Journal:  Nat Genet       Date:  2015-10-05       Impact factor: 38.330

6.  Next-Gen Sequencing Exposes Frequent MED12 Mutations and Actionable Therapeutic Targets in Phyllodes Tumors.

Authors:  Andi K Cani; Daniel H Hovelson; Andrew S McDaniel; Seth Sadis; Michaela J Haller; Venkata Yadati; Anmol M Amin; Jarred Bratley; Santhoshi Bandla; Paul D Williams; Kate Rhodes; Chia-Jen Liu; Michael J Quist; Daniel R Rhodes; Catherine S Grasso; Celina G Kleer; Scott A Tomlins
Journal:  Mol Cancer Res       Date:  2015-01-15       Impact factor: 5.852

7.  Molecular pathogenesis of progression and recurrence in breast phyllodes tumors.

Authors:  Ana Richelia Jara-Lazaro; Puay Hoon Tan
Journal:  Am J Transl Res       Date:  2009-01-01       Impact factor: 4.060

8.  Malignant phyllodes tumour with liposarcomatous differentiation, invasive tubular carcinoma, and ductal and lobular carcinoma in situ: case report and review of the literature.

Authors:  Mardiana Abdul Aziz; Frank Sullivan; Michael J Kerin; Grace Callagy
Journal:  Patholog Res Int       Date:  2010-07-05

9.  Borderline and malignant phyllodes tumors display similar promoter methylation profiles.

Authors:  Jo-Heon Kim; Yoo Duk Choi; Ji Shin Lee; Jae Hyuk Lee; Jong Hee Nam; Chan Choi; Min Ho Park; Jung Han Yoon
Journal:  Virchows Arch       Date:  2009-11-19       Impact factor: 4.064

10.  A subset of malignant phyllodes tumors harbors alterations in the Rb/p16 pathway.

Authors:  Ashley Cimino-Mathews; Jessica L Hicks; Rajni Sharma; Russell Vang; Peter B Illei; Angelo De Marzo; Leisha A Emens; Pedram Argani
Journal:  Hum Pathol       Date:  2013-07-31       Impact factor: 3.466

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.